AAPL Research Note — Next Evidence Window
Services strength and China growth face a leadership transition, legal pressure and a premium valuation.
Research Notes
LLY Research Note — Share Lead Meets Valuation
Lilly’s Q2 revenue rose 48% as category share widened, leaving paid access and recurring margins as the next valuation tests.
GLD Research Note — Gold Hedge Faces Its Test
GLD’s hedge case improved as labor weakened and energy inflation rose, but the five-day rebound left the tactical setup exposed to real yields and geopolitics.
COST Research Note — Durable Franchise, Macro Test
Costco’s membership economics remain strong, but rates and September evidence must continue to support its premium valuation.
ACGL Research Note — The Turn Is Not Confirmed
Strong underwriting meets cycle pressure, macro risk and unresolved relative weakness in Arch Capital.
WST Research Note — The Multiple Faces CPI
West Pharmaceutical is growing with net cash, but CPI and Treasury yields will test whether its premium multiple can hold.
SPCX Research Note — Supply Calendar Still Open
SPCX recovered above its issue price after the first ownership release, but November reporting and December supply keep the evidence incomplete.
ASML Research Note — The Cycle Needs Its Own Proof
ASML’s operating quality and TSM demand support the cycle, but bookings and export-policy evidence remain the missing confirmation.
QQQ Research Note — Three Tests for the Recovery
QQQ recovered above its 50-day average, but CPI, Treasury yields and two semiconductor reports will test whether the rebound can broaden.
JPM Research Note — Quality at a Full Price
JPMorgan’s operating strength remains clear, but peak valuation and incomplete credit visibility leave little room for disappointment.